Revision Skin has pioneered the use of peptides to develop technologies and conduct ingredient research to create clinically validated, high-potency products that enhance the skin. RVL Pharmaceuticals offers patients a non-surgical solution for acquired ptosis and provides quick results with UPNEEQ.
"We are thrilled to partner with Revision Skincare. Their strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics," said Brian Markison, CEO of RVL Pharmaceuticals.
Through the partnership, the companies will bring broader access to innovations like D·E·J Eye Cream, Revox Line Relaxer and UPNEEQ. The collaboration will launch a variety of marketing efforts within the medical aesthetics industry, working together to address provider and consumer needs.